LS CancerDiag Oy. LS CancerDiag is a diagnostics company that has developed a breakthrough technology called DiagMMR for diagnosing Lynch syndrome, the most common hereditary cancer syndrome worldwide. The company’s unique technological innovation is the result of over ten years of academic research. With this innovation, individuals who have inherited the syndrome can be identified at an early stage and directed towards cancer-preventive monitoring.
The DiagMMR method is protected in 29 countries, and the target market formed by these countries is valued at $1.6 billion. LS CancerDiag’s vision is to make DiagMMR a global testing standard for diagnosing Lynch syndrome.
The company’s primary market is the United States, and this target market is valued at $200 million annually. The company aims to achieve approximately $35 million in revenue in the target market by 2027.
LS CancerDiag conducted a 5.4 million euro share issue in March 2023 with Springvest as organizer, attracting 600 investors. Biggest shareholders Lehto Invest and TJT Technologies.
Investment in year 2023.